NYSE:ABT - Abbott Laboratories Stock Price, Price Target & More

$59.19 -0.69 (-1.15 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$59.19

Today's Range$58.8150 - $59.97

52-Week Range$42.88 - $64.60

Volume5.73 million shs

Average Volume7.11 million shs

Market Capitalization$103.94 billion

P/E Ratio23.68

Dividend Yield1.88%

Beta1.5

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNYSE:ABT

CUSIP00282410

Webwww.abbott.com

Phone224-667-6100

Debt

Debt-to-Equity Ratio0.87%

Current Ratio2.26%

Quick Ratio1.86%

Price-To-Earnings

Trailing P/E Ratio23.68

Forward P/E Ratio20.70

P/E Growth1.76

Sales & Book Value

Annual Sales$27.39 billion

Price / Sales3.77

Cash Flow$4.7619 per share

Price / Cash12.43

Book Value$17.87 per share

Price / Book3.31

Profitability

EPS (Most Recent Fiscal Year)$2.50

Net Income$477 million

Net Margins1.67%

Return on Equity14.53%

Return on Assets6.29%

Miscellaneous

Employees99,000

Outstanding Shares1,746,330,000

How to Become a New Pot Stock Millionaire

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, February 16th. Investors of record on Friday, April 13th will be given a dividend of $0.28 per share on Tuesday, May 15th. This represents a $1.12 annualized dividend and a yield of 1.89%. The ex-dividend date is Thursday, April 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) released its earnings results on Wednesday, April, 18th. The healthcare product maker reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.01. The healthcare product maker earned $7.39 billion during the quarter, compared to the consensus estimate of $7.28 billion. Abbott Laboratories had a net margin of 1.67% and a return on equity of 14.53%. The business's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.48 EPS. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, July, 19th 2018. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY18 earnings guidance on Wednesday, April, 18th. The company provided earnings per share (EPS) guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.86. Abbott Laboratories also updated its Q2 guidance to $0.70-0.72 EPS.

What price target have analysts set for ABT?

18 brokerages have issued 12-month price objectives for Abbott Laboratories' shares. Their predictions range from $45.00 to $80.00. On average, they anticipate Abbott Laboratories' share price to reach $67.00 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

Some companies that are related to Abbott Laboratories include Novartis (NVS), Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN) and Astellas Pharma (ALPMY).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

Mr. Miles D. White, Chairman & CEO (Age 63)
Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
Mr. Brian J. Blaser, Exec. VP of Diagnostic Products (Age 53)
Scott M. Leinenweber, VP of Investor Relations
Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)

Has Abbott Laboratories been receiving favorable news coverage?

Headlines about ABT stock have been trending somewhat negative recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Abbott Laboratories earned a media sentiment score of -0.01 on Accern's scale. They also assigned news articles about the healthcare product maker an impact score of 47.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $59.19.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $103.94 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.

MarketBeat Community Rating for Abbott Laboratories (ABT)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		639 (Vote Outperform)
Underperform Votes:		486 (Vote Underperform)
Total Votes:		1,125

MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Abbott Laboratories (NYSE:ABT) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for Abbott Laboratories in the last 12 months. Their average twelve-month price target is $67.00, suggesting that the stock has a possible upside of 13.19%. The high price target for ABT is $80.00 and the low price target for ABT is $45.00. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.78	2.74	2.76	2.60
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$67.00	$65.5556	$60.00	$56.5333
Price Target Upside:	13.19% upside	4.30% upside	1.16% upside	1.37% upside

Abbott Laboratories (NYSE:ABT) Consensus Price Target History

Price Target History for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/30/2018	Argus	Boost Price Target	Buy	$66.00 -> $80.00	Low
1/30/2018	Citigroup	Boost Price Target	Neutral -> Neutral	$59.00 -> $64.00	Low
1/25/2018	Barclays	Boost Price Target	Overweight -> Overweight	$66.00 -> $70.00	Low
1/25/2018	Guggenheim	Reiterated Rating	Buy	$72.00	Low
1/25/2018	Royal Bank of Canada	Reiterated Rating	Buy	$67.00	Low
1/25/2018	Leerink Swann	Reiterated Rating	Market Perform	$60.00 -> $68.00	Low
1/25/2018	JPMorgan Chase	Boost Price Target	Overweight -> Overweight	$65.00 -> $69.00	High
1/25/2018	Morgan Stanley	Boost Price Target	Overweight -> Overweight	$67.00 -> $70.00	High
1/25/2018	Wells Fargo	Boost Price Target	Outperform	$66.00 -> $70.00	Medium
1/25/2018	BMO Capital Markets	Boost Price Target	Outperform -> Outperform	$65.00 -> $70.00	Medium
1/25/2018	Stifel Nicolaus	Boost Price Target	Buy -> Buy	$63.00 -> $71.00	Medium
1/25/2018	William Blair	Upgrade	Market Perform -> Outperform		Medium
1/24/2018	Bank of America	Boost Price Target		$60.00 -> $70.00	High
1/22/2018	BTIG Research	Downgrade	Buy -> Neutral		Medium
1/3/2018	Evercore ISI	Initiated Coverage	Outperform -> Outperform	$64.00	Low
10/19/2017	Cowen	Set Price Target	Buy	$55.00 -> $68.00	N/A
10/19/2017	Jefferies Group	Reiterated Rating	Buy	$65.00	N/A
5/16/2017	Goldman Sachs	Initiated Coverage	Neutral -> Neutral	$45.00	Low
4/18/2017	UBS	Reiterated Rating	Neutral	$41.00	N/A
8/9/2016	Deutsche Bank	Reiterated Rating	Buy		N/A
6/21/2016	Edward Jones	Upgrade	Hold -> Buy		N/A
6/8/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A
4/30/2016	S&P Equity Research	Reiterated Rating	Hold		N/A
4/30/2016	Gabelli	Reiterated Rating	Buy		N/A
4/28/2016	Piper Jaffray	Downgrade	Overweight -> Neutral		N/A

(Data available from 4/20/2016 forward)

Abbott Laboratories (NYSE:ABT) Earnings History and Estimates Chart

Earnings by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Earnings Estimates

2018 EPS Consensus Estimate: $2.85
2019 EPS Consensus Estimate: $3.20

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.57	$0.58	$0.57
Q2 2018	3	$0.69	$0.72	$0.71
Q3 2018	3	$0.72	$0.75	$0.73
Q4 2018	3	$0.82	$0.84	$0.83
Q1 2019	2	$0.66	$0.66	$0.66
Q2 2019	2	$0.79	$0.79	$0.79
Q3 2019	2	$0.82	$0.83	$0.83
Q4 2019	2	$0.92	$0.93	$0.93

Abbott Laboratories (NYSE ABT) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/19/2018
4/18/2018	Q1 18	$0.58	$0.59	$7.2831 billion	$7.39 billion	View	N/A
1/24/2018	Q4 2017	$0.73	$0.74	$7.3844 billion	$7.5890 billion	View	Listen
10/18/2017	9/30/2017	$0.65	$0.66	$6.7160 billion	$6.8290 billion	View	N/A
7/20/2017	Q2 2017	$0.60	$0.62	$6.6273 billion	$6.6370 billion	View	N/A
4/19/2017	3/31/2017	$0.43	$0.48	$6.1623 billion	$6.3350 billion	View	N/A
1/25/2017	Q416	$0.64	$0.65	$5.41 billion	$5.33 billion	View	Listen
10/19/2016	Q316	$0.58	$0.59	$5.29 billion	$5.30 billion	View	Listen
7/20/2016	Q216	$0.53	$0.55	$5.24 billion	$5.30 billion	View	Listen
4/20/2016	Q116	$0.39	$0.41	$4.77 billion	$4.90 billion	View	Listen
1/28/2016	Q415	$0.61	$0.62	$5.31 billion	$5.20 billion	View	Listen
10/21/2015	Q315	$0.53	$0.54	$5.16 billion	$5.15 billion	View	Listen
7/22/2015	Q215	$0.50	$0.52	$5.15 billion	$5.20 billion	View	Listen
4/22/2015	Q115	$0.42	$0.47	$4.85 billion	$4.90 billion	View	Listen
1/29/2015	Q414	$0.68	$0.71	$5.48 billion	$5.36 billion	View	Listen
10/22/2014	Q314	$0.60	$0.62	$5.62 billion	$5.10 billion	View	Listen
7/16/2014	Q214	$0.51	$0.54	$5.53 billion	$5.55 billion	View	Listen
4/16/2014	Q114	$0.36	$0.41	$5.29 billion	$5.24 billion	View	Listen
1/22/2014	Q413	$0.58	$0.58	$5.72 billion	$5.66 billion	View	Listen
10/16/2013	Q313	$0.52	$0.55	$5.46 billion	$5.37 billion	View	Listen
7/17/2013	Q2 2013	$0.44	$0.46	$5.53 billion	$5.45 billion	View	Listen
4/17/2013	Q1 2013	$0.41	$0.42	$5.42 billion	$5.38 billion	View	Listen
1/23/2013	Q4 2012	$1.50	$1.51	$10.58 billion	$10.80 billion	View	Listen
10/17/2012		$1.28	$1.30			View	N/A
7/18/2012		$1.22	$1.23			View	N/A
4/18/2012		$1.00	$1.03			View	N/A
1/25/2012		$1.44	$1.45			View	N/A
10/19/2011		$1.17	$1.18			View	N/A
7/20/2011		$1.12	$1.12			View	N/A
4/20/2011		$0.90	$0.91			View	N/A
1/26/2011		$1.29	$1.30			View	N/A
10/20/2010	Q3 2010	$1.04	$1.05			View	N/A
7/21/2010	Q2 2010	$1.00	$1.01			View	N/A
4/21/2010	Q1 2010	$0.80	$0.81			View	N/A
1/27/2010	Q4 2009	$1.17	$1.18			View	N/A
10/14/2009	Q3 2009	$0.90	$0.92			View	N/A
7/15/2009	Q2 2009	$0.89	$0.90			View	N/A
4/15/2009	Q1 2009	$0.70	$0.73			View	N/A
1/21/2009	Q4 2008	$1.06	$1.06			View	N/A
10/15/2008	Q3 2008	$0.77	$0.79			View	N/A
7/16/2008	Q2 2008	$0.78	$0.84			View	N/A
4/16/2008	Q1 2008	$0.63	$0.63			View	N/A
1/23/2008	Q4 2007	$0.92	$0.93			View	N/A

(Earnings results data provided by Zacks Investment Research)

Abbott Laboratories (NYSE:ABT) Dividend Information

Abbott Laboratories pays an annual dividend of $1.12 per share, with a dividend yield of 1.89%. ABT's next quarterly dividend payment will be made on Tuesday, May 15. The company has grown its dividend for the last 45 consecutive years and is increasing its dividend by an average of 6.40% each year. Abbott Laboratories pays out 44.80% of its earnings out as a dividend.

Next Dividend:	5/15/2018
Annual Dividend:	$1.12
Dividend Yield:	1.89%
Dividend Growth:	6.40% (3 Year Average)
Payout Ratio:	44.80% (Trailing 12 Months of Earnings) 39.16% (Based on This Year's Estimates) 34.78% (Based on Next Year's Estimates)
Track Record:	45 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/16/2018	quarterly	$0.28	1.85415114642828%	4/12/2018	4/13/2018	5/15/2018
12/15/2017	quarterly	$0.28	1.99%	1/11/2018	1/12/2018	2/15/2018
9/15/2017	quarterly	$0.2650	2.05%	10/12/2017	10/13/2017	11/15/2017
6/9/2017	quarterly	$0.2650	2.25%	7/12/2017	7/14/2017	8/15/2017
2/17/2017	quarterly	$0.2650	2.36%	4/11/2017	4/14/2017	5/15/2017
12/9/2016	quarterly	$0.2650	2.7%	1/11/2017	1/13/2017	2/15/2017
9/15/2016	quarterly	$0.26	2.48%	10/12/2016	10/14/2016	11/15/2016
6/10/2016	quarterly	$0.26	2.75%	7/13/2016	7/15/2016	8/15/2016
2/19/2016	quarterly	$0.26	2.66%	4/13/2016	4/15/2016	5/16/2016
12/11/2015	quarterly	$0.26	2.32%	1/13/2016	1/15/2016	2/16/2016
9/17/2015	quarterly	$0.24	2.22%	10/13/2015	10/15/2015	11/15/2015
6/12/2015	quarterly	$0.24	2%	7/13/2015	7/15/2015	8/15/2015
2/20/2015	quarterly	$0.24	2.03%	4/13/2015	4/15/2015	5/15/2015
12/12/2014	quarterly	$0.24	2.21%	1/13/2015	1/15/2015	2/13/2015
9/11/2014	quarterly	$0.22	2.07%	10/10/2014	10/15/2014	11/15/2014
6/13/2014	quarterly	$0.22	2.21%	7/11/2014	7/15/2014	8/15/2014
2/21/2014	quarterly	$0.22	2.26%	4/11/2014	4/15/2014	5/15/2014
10/16/2013	quarterly	$0.22	2.37%	1/13/2014	1/15/2014	2/15/2014
9/12/2013	quarterly	$0.14	1.61%	10/10/2013	10/15/2013	11/15/2013
6/14/2013	quarterly	$0.14	1.52%	7/11/2013	7/15/2013	8/15/2013
2/15/2013	quarterly	$0.14	1.61%	4/11/2013	4/15/2013	5/15/2013
12/14/2012	quarterly	$0.14	0.86%	1/11/2013	1/15/2013	2/15/2013

(Data available from 1/1/2013 forward)

Abbott Laboratories (NYSE ABT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 72.34%

Insider Trading History for Abbott Laboratories (NYSE:ABT)

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE ABT) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/9/2018	Roger Bird	Insider	Sell	8,262	$62.75	$518,440.50	58,574
3/7/2018	Jared Watkin	Insider	Sell	3,000	$61.19	$183,570.00	68,215
3/5/2018	Sharon J Bracken	SVP	Sell	2,100	$60.27	$126,567.00	44,790
3/1/2018	Jared Watkin	SVP	Sell	996	$58.87	$58,634.52	69,511
3/1/2018	Sharon J Bracken	Insider	Sell	1,053	$58.93	$62,053.29
3/1/2018	Stephen R Fussell	EVP	Sell	11,106	$60.13	$667,803.78	172,158
2/27/2018	Daniel J Starks	Director	Buy	40,037	$60.67	$2,429,044.79	6,943,348
2/20/2018	Jared Watkin	SVP	Sell	297	$59.29	$17,609.13	74,357
2/20/2018	Stephen R Fussell	Insider	Sell	56,401	$59.61	$3,362,063.61	184,884
1/31/2018	Brian J Blaser	Insider	Sell	27,733	$62.26	$1,726,656.58	156,587
1/30/2018	Stephen R Fussell	EVP	Sell	13,313	$62.84	$836,588.92	152,343
12/14/2017	Daniel Gesua Sive Salvadori	Insider	Sell	28,319	$54.92	$1,555,279.48	102,117
12/6/2017	Miles D White	Chairman	Sell	276,886	$54.41	$15,065,367.26	3,677,913
11/30/2017	Sharon J Bracken	Insider	Sell	2,188	$56.12	$122,790.56	25,618
11/22/2017	Alejandro D Wellisch	Insider	Sell	2,153	$55.86	$120,266.58	10,256
11/17/2017	Brian J Blaser	Insider	Sell	23,866	$55.55	$1,325,756.30	146,387
11/14/2017	Daniel Gesua Sive Salvadori	Insider	Sell	71,157	$55.00	$3,913,635.00	144,955
10/23/2017	Daniel Gesua Sive Salvadori	EVP	Sell	96,603	$56.21	$5,430,054.63	142,082
9/26/2017	Daniel Gesua Sive Salvadori	Insider	Sell	62,460	$52.95	$3,307,257.00	113,426
9/22/2017	Jaime Contreras	Insider	Sell	52,700	$51.97	$2,738,819.00	58,739
8/16/2017	Stephen R Fussell	Insider	Sell	196,550	$49.50	$9,729,225.00	221,488
8/1/2017	Sharon J Bracken	Insider	Sell	2,000	$49.16	$98,320.00	28,806
7/27/2017	Brian J Blaser	Insider	Sell	15,000	$50.00	$750,000.00	143,154
7/25/2017	Hubert L Allen	Insider	Sell	4,600	$50.79	$233,634.00	105,479
6/15/2017	Jared Watkin	Insider	Sell	552	$47.97	$26,479.44	47,090
6/8/2017	Stephen R Fussell	Insider	Sell	196,550	$46.00	$9,041,300.00	221,488
4/27/2017	Roger Bird	Insider	Sell	5,600	$43.82	$245,392.00	51,313
4/26/2017	Joseph J Manning	Insider	Sell	4,200	$43.95	$184,590.00	26,224
3/1/2017	Michael J. Warmuth	Insider	Sell	3,851	$45.39	$174,796.89
2/23/2017	Robert E Funck	VP	Sell	25,500	$45.50	$1,160,250.00	117,579
2/22/2017	Roger Bird	Insider	Sell	13,222	$45.02	$595,254.44	63,910
2/21/2017	Deepak S Nath	Insider	Sell	319	$44.98	$14,348.62	58,471
1/31/2017	Heather L Mason	Insider	Sell	35,700	$40.77	$1,455,489.00	100,189
12/20/2016	Brian J Blaser	Insider	Buy	15,580	$38.45	$599,051.00	129,782
12/14/2016	Robert B Ford	Insider	Buy	12,775	$39.09	$499,374.75	51,532
11/10/2016	Miles D White	Chairman	Buy	121,456	$40.45	$4,912,895.20	2,802,558
11/1/2016	Sally E Blount	Director	Buy	5,100	$39.24	$200,124.00	20,143
9/26/2016	Daniel Gesua Sive Salvadori	SVP	Sell	815	$41.71	$33,993.65	59,791
7/28/2016	Stephen R Fussell	Insider	Sell	41,500	$45.00	$1,867,500.00	196,467
7/26/2016	Michael J Warmuth	Insider	Sell	26,800	$43.49	$1,165,532.00	81,811
7/25/2016	Miles D White	Chairman	Buy	242,547	$43.18	$10,473,179.46	2,010,517
7/25/2016	Robert E Funck	VP	Sell	26,800	$43.08	$1,154,544.00	111,819
6/28/2016	Hubert L Allen	EVP	Sell	3,400	$37.14	$126,276.00	91,857
6/15/2016	Jared Watkin	SVP	Sell	552	$37.63	$20,771.76	47,114
6/1/2016	Brian B Yoor	CFO	Sell	565	$39.49	$22,311.85	50,182
4/28/2016	Deepak S Nath	SVP	Sell	53	$41.31	$2,189.43	47,435
3/31/2016	Jaime Contreras	SVP	Sell	462	$41.78	$19,302.36	47,667
2/29/2016	Brian B Yoor	CFO	Sell	865	$39.12	$33,838.80	52,250
2/29/2016	Deepak S Nath	SVP	Sell	793	$39.27	$31,141.11	48,364
2/29/2016	Robert B Ford	EVP	Sell	1,706	$39.28	$67,011.68	62,495
2/29/2016	Robert E Funck	VP	Sell	1,333	$39.30	$52,386.90	86,352
2/22/2016	Jared Watkin	SVP	Sell	554	$39.09	$21,655.86	50,515
2/16/2016	Deepak S. Nath	SVP	Sell	171	$37.13	$6,349.23	34,941
12/16/2015	Miles D. White	CEO	Sell	438,000	$46.00	$20,148,000.00	1,394,153
8/18/2015	Stephen R. Fussell	EVP	Sell	13,096	$50.46	$660,824.16	130,601
4/27/2015	Heather L Mason	EVP	Sell	13,500	$47.45	$640,575.00
4/27/2015	Roger Bird	SVP	Sell	28,548	$47.57	$1,358,028.36
3/26/2015	J. Scott White	SVP	Sell	12,483	$46.68	$582,706.44
3/2/2015	Jaime Contreras	SVP	Sell	9,209	$47.34	$435,954.06
2/4/2015	John M Capek	EVP	Sell	34,292	$45.66	$1,565,772.72
11/25/2014	Jaime Contreras	SVP	Sell	51,600	$44.07	$2,274,012.00
10/29/2014	Miles D White	CEO	Sell	440,800	$42.52	$18,742,816.00
3/3/2014	John Landgraf	EVP	Sell	17,293	$39.38	$680,998.34	95,131
3/3/2014	Katherine Doyle	SVP	Sell	6,639	$39.01	$258,987.39	47,525
3/3/2014	Robert Funck	VP	Sell	1,413	$38.97	$55,064.61	62,926
2/18/2014	John Landgraf	EVP	Sell	1,583	$39.10	$61,895.30	102,421
1/29/2014	Michael Warmuth	EVP	Sell	11,430	$36.21	$413,880.30	40,487
12/6/2013	Jean-Yves Pavee	SVP	Sell	5,855	$37.46	$219,328.30	30,901
11/7/2013	Stephen Fussell	EVP	Sell	10,466	$37.59	$393,416.94	101,169
10/30/2013	Jaime Contreras	SVP	Sell	25,368	$36.85	$934,810.80
6/7/2013	Heather L Mason	SVP	Sell	12,000	$37.01	$444,120.00
2/1/2013	William A Osborn	Director	Buy	10,000	$33.86	$338,600.00

(Data available from 1/1/2013 forward)

Abbott Laboratories (NYSE ABT) News Headlines

Source:

Date	Headline
	Abbott Laboratories (ABT) Coverage Initiated by Analysts at BTIG Research www.americanbankingnews.com - April 20 at 6:24 PM
	Top Analyst Reports for Goldman Sachs, Abbott & Altria finance.yahoo.com - April 20 at 5:20 PM
	Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023 finance.yahoo.com - April 20 at 5:20 PM
	Abbott Laboratories (ABT) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - April 20 at 11:54 AM
	Earnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% Sensitive www.nasdaq.com - April 20 at 8:33 AM
	FY2018 EPS Estimates for Abbott Laboratories Increased by William Blair (ABT) www.americanbankingnews.com - April 20 at 8:32 AM
	Abbott Laboratories (ABT) to Post Q3 2018 Earnings of $0.73 Per Share, Leerink Swann Forecasts www.americanbankingnews.com - April 20 at 8:08 AM
	Jefferies Group Weighs in on Abbott Laboratories' Q3 2018 Earnings (ABT) www.americanbankingnews.com - April 20 at 8:08 AM
	Abbott Laboratories (ABT) Earns Hold Rating from BMO Capital Markets www.americanbankingnews.com - April 19 at 5:50 PM
	Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves finance.yahoo.com - April 19 at 5:32 PM
	Abbott Laboratories (ABT) Q1 2018 Earnings Conference Call Transcript www.msn.com - April 19 at 8:52 AM
	Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained www.zacks.com - April 18 at 5:12 PM
	Abbott Laboratories' (ABT) CEO Miles White on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - April 18 at 5:12 PM
	Abbott CEO: New Glucose Device's U.S. Launch 'Has Gone Exceptionally Well' www.thestreet.com - April 18 at 5:12 PM
	Is Abbott Laboratories’s (NYSE:ABT) Balance Sheet Strong Enough To Weather A Storm? finance.yahoo.com - April 18 at 5:12 PM
	Abbott Shares Topple After Pharma Unit Struggles In First Quarter finance.yahoo.com - April 18 at 5:12 PM
	Abbott Laboratories Stock Slips Despite Earnings Beat investorplace.com - April 18 at 1:13 PM
	Earnings In Focus: Apr. 18 (ABT, PIR, STLD) www.finanznachrichten.de - April 18 at 8:53 AM
	Abbott Laboratories Q1 adjusted earnings Beat Estimates www.nasdaq.com - April 18 at 8:53 AM
	Abbott Labs' quarterly revenue rises 16.7 percent www.reuters.com - April 18 at 8:53 AM
	Abbott (ABT) Beats on Earnings and Revenues in Q1 www.zacks.com - April 18 at 8:53 AM
	Abbott: 1Q Earnings Snapshot finance.yahoo.com - April 18 at 8:53 AM
	Abbott Reports First-Quarter 2018 Results finance.yahoo.com - April 18 at 8:53 AM
	Abbott's quarterly profit, sales beat Street estimates finance.yahoo.com - April 18 at 8:53 AM
	Abbott Laboratories Tops Q1 Earnings Estimates, Issues Full Year Guidance finance.yahoo.com - April 18 at 8:53 AM
	Abbott Labs beats profit and sales expectations, shares slip finance.yahoo.com - April 18 at 8:53 AM
	Abbott Laboratories Earnings Top Views On Solid Organic Sales finance.yahoo.com - April 18 at 8:53 AM
	Abbott Laboratories (ABT) Issues Q2 Earnings Guidance www.americanbankingnews.com - April 18 at 8:50 AM
	Abbott Laboratories (ABT) Issues FY18 Earnings Guidance www.americanbankingnews.com - April 18 at 8:50 AM
	Abbott Laboratories (ABT) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS www.americanbankingnews.com - April 18 at 8:50 AM
	Analysts Anticipate Abbott Laboratories (ABT) Will Post Quarterly Sales of $7.26 Billion www.americanbankingnews.com - April 18 at 3:02 AM
	Abbott's New Ensure® Max Protein Helps Americans Go for Their #HealthGoals finance.yahoo.com - April 17 at 5:23 PM
	Glucose Monitoring Device in Focus as Abbott Preps to Unveil Earnings finance.yahoo.com - April 17 at 5:23 PM
	3 Stocks to Buy Ahead of Earnings finance.yahoo.com - April 16 at 5:22 PM
	Is Abbott Laboratories (NYSE:ABT) Worth $58.49 Based On Intrinsic Value? finance.yahoo.com - April 16 at 5:22 PM
	Zacks: Analysts Expect Abbott Laboratories (ABT) to Announce $0.58 Earnings Per Share www.americanbankingnews.com - April 16 at 1:08 PM
	BidaskClub Lowers Abbott Laboratories (ABT) to Buy www.americanbankingnews.com - April 15 at 12:36 AM
	Abbott Laboratories (ABT) Given "Buy" Rating at Jefferies Group www.americanbankingnews.com - April 13 at 11:43 PM
	Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings? finance.yahoo.com - April 13 at 5:19 PM
	Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings? finance.yahoo.com - April 13 at 5:19 PM
	Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings? www.zacks.com - April 12 at 9:04 AM
	Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease finance.yahoo.com - April 11 at 5:13 PM
	Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings? finance.yahoo.com - April 11 at 5:13 PM
	Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings? www.zacks.com - April 11 at 8:50 AM
	Abbott Laboratories (ABT) to Release Quarterly Earnings on Wednesday www.americanbankingnews.com - April 11 at 1:34 AM
	Abbott Laboratories Stock Performance in 1Q18 finance.yahoo.com - April 10 at 5:17 PM
	New Trial Data Show Improved Clinical Outcomes with HeartMate3 finance.yahoo.com - April 9 at 5:18 PM
	Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Abbott Laboratories, ABIOMED, Align Technology, and Avinger www.bizjournals.com - April 9 at 9:04 AM
	Abbott Laboratories' (ABT) Buy Rating Reiterated at Royal Bank of Canada www.americanbankingnews.com - April 8 at 11:01 AM
	Abbott Laboratories (ABT) Raised to Buy at Zacks Investment Research www.americanbankingnews.com - April 7 at 9:11 AM

Abbott Laboratories (NYSE:ABT) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Abbott Laboratories (NYSE:ABT) Income Statement, Balance Sheet and Cash Flow Statement

Abbott Laboratories (NYSE ABT) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff